QBie™ Spotlight: Zelda Therapeutics Ltd. (OTCQB: ZLDAF)
What does Zelda Therapeutics do?
Dr. Stewart Washer (Executive Director – OTCQB: ZLDAF): “Zelda Therapeutics is working on a number of clinical studies using cannabis to treat insomnia and autism symptoms. These are being run in Australia, Chile and an observational study on Autism in the USA. We also have a number of pre-clinical studies in looking at the effects of cannabis extracts on cancer, namely breast, pancreatic and brain. We have some very good results in the breast cancer area where we showed the cannabis extracts were similar to the leading chemotherapy agents in reducing tumour growth.
These clinical and preclinical studies may result in valuable cannabis medicines that can be partnered or licensed to larger companies to take through to market.”
What is the next big goal the ZLDAF is trying to accomplish/what should we keep an eye out for?
Dr. Stewart Washer: “I would suggest the Insomnia study starting in Australia could be a world first in a very wide spread disorder that effects around a third of the adult population.”
Why did you join the OTCQB/go public?
Dr. Stewart Washer: “There was interest building in the region in cannabis companies with high quality research projects to invest into.”
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.